Identification

Name
Androstenedione
Accession Number
DB01536  (EXPT00569, DB07386)
Type
Small Molecule
Groups
Experimental, Illicit
Description

A delta-4 C19 steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol.

Structure
Thumb
Synonyms
  • 4-Androstene-3,17-dione
  • 4-Androstenedione
Categories
UNII
409J2J96VR
CAS number
63-05-8
Weight
Average: 286.4085
Monoisotopic: 286.193280076
Chemical Formula
C19H26O2
InChI Key
AEMFNILZOJDQLW-QAGGRKNESA-N
InChI
InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1
IUPAC Name
(1S,2R,10R,11S,15S)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-5,14-dione
SMILES
[H][[email protected]@]12CCC(=O)[[email protected]@]1(C)CC[[email protected]@]1([H])[[email protected]@]2([H])CCC2=CC(=O)CC[[email protected]]12C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

4-androstenedione is a 19-carbon steroid hormone produced in the adrenal glands and the gonads as an intermediate step in the biochemical pathway that produces the androgen testosterone and the estrogens estrone and estradiol.

TargetActionsOrganism
AEstradiol 17-beta-dehydrogenase 1
inducer
Human
A3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
positive allosteric modulator
Human
U6-deoxyerythronolide B hydroxylase
inducer
Saccharopolyspora erythraea (strain NRRL 23338)
UAldo-keto reductase family 1 member C3
inducer
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Aromatase deficiencyDisease
Androgen and Estrogen MetabolismMetabolic
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDisease
Androstenedione MetabolismMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Androstenedione is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Androstenedione.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Androstenedione.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Androstenedione.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Androstenedione.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Androstenedione.Approved, Withdrawn
AldesleukinAndrostenedione may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Androstenedione can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Androstenedione.Experimental
AloglutamolThe bioavailability of Androstenedione can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Androstenedione.Experimental
AluminiumThe bioavailability of Androstenedione can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Androstenedione can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Androstenedione can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Androstenedione can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Androstenedione is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Androstenedione.Approved
AmiodaroneThe serum concentration of Androstenedione can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BAndrostenedione may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Androstenedione.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Androstenedione.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Androstenedione.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Androstenedione.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Androstenedione.Approved, Investigational
AprepitantThe serum concentration of Androstenedione can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Androstenedione can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Androstenedione.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Androstenedione.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Androstenedione.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Androstenedione.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Androstenedione is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Androstenedione.Experimental
BendroflumethiazideAndrostenedione may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Androstenedione.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Androstenedione.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Androstenedione.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Androstenedione.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Androstenedione.Experimental
Bismuth SubcitrateThe bioavailability of Androstenedione can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Androstenedione can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Androstenedione can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Androstenedione.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Androstenedione.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Androstenedione.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Androstenedione.Experimental
BumetanideAndrostenedione may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Androstenedione.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Androstenedione can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Androstenedione can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideAndrostenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Androstenedione can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Androstenedione.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Androstenedione.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Androstenedione.Approved, Investigational
CeritinibAndrostenedione may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Androstenedione.Approved, Vet Approved
ChlorothiazideAndrostenedione may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Androstenedione can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneAndrostenedione may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Androstenedione.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Androstenedione can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Androstenedione.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Androstenedione is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Androstenedione can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Androstenedione can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Androstenedione.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Androstenedione is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Androstenedione is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Androstenedione.Investigational
CyclopenthiazideAndrostenedione may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Androstenedione.Investigational
DaidzeinThe serum concentration of Androstenedione can be increased when it is combined with Daidzein.Experimental
DanazolAndrostenedione may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Androstenedione can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Androstenedione is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Androstenedione is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Androstenedione is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Androstenedione.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Androstenedione is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Androstenedione.Approved, Vet Approved
DienestrolThe serum concentration of Androstenedione can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Androstenedione can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Androstenedione.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Androstenedione.Approved
DihydrotestosteroneAndrostenedione may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Androstenedione is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Androstenedione.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Androstenedione.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Androstenedione.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Androstenedione is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Androstenedione is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Androstenedione can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Androstenedione can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Androstenedione.Approved
EquolThe serum concentration of Androstenedione can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Androstenedione can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Androstenedione can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Androstenedione can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Androstenedione can be increased when it is combined with Estrone.Approved
Etacrynic acidAndrostenedione may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Androstenedione.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Androstenedione.Experimental
Ethinyl EstradiolThe serum concentration of Androstenedione can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Androstenedione.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Androstenedione.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Androstenedione.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Androstenedione.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Androstenedione.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Androstenedione.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Androstenedione.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Androstenedione.Approved
FenthionThe risk or severity of adverse effects can be increased when Androstenedione is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Androstenedione.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Androstenedione.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Androstenedione.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Androstenedione.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Androstenedione.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Androstenedione.Experimental
FluoxymesteroneAndrostenedione may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Androstenedione.Approved, Investigational
FosaprepitantThe serum concentration of Androstenedione can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Androstenedione can be decreased when it is combined with Fosphenytoin.Approved
FurosemideAndrostenedione may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Androstenedione is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Androstenedione is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Androstenedione can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Androstenedione is combined with GI-5005.Investigational
GLPG-0492Androstenedione may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Androstenedione.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Androstenedione.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Androstenedione.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Androstenedione is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Androstenedione can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Androstenedione.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Androstenedione is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Androstenedione.Approved, Investigational
HydrochlorothiazideAndrostenedione may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAndrostenedione may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Androstenedione can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Androstenedione.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Androstenedione.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Androstenedione.Approved
IdelalisibThe serum concentration of Androstenedione can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Androstenedione.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Androstenedione.Approved
IndapamideAndrostenedione may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Androstenedione can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Androstenedione.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Androstenedione.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Androstenedione.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Androstenedione is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Androstenedione is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Androstenedione is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Androstenedione.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Androstenedione.Withdrawn
ItraconazoleThe serum concentration of Androstenedione can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Androstenedione.Experimental
KetoconazoleThe serum concentration of Androstenedione can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Androstenedione.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Androstenedione.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Androstenedione.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Androstenedione.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Androstenedione.Experimental
LopinavirThe serum concentration of Androstenedione can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Androstenedione.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Androstenedione.Approved, Investigational
LumacaftorThe serum concentration of Androstenedione can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Androstenedione.Approved, Investigational
MagaldrateThe bioavailability of Androstenedione can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Androstenedione can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Androstenedione can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Androstenedione can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Androstenedione.Approved
Magnesium silicateThe bioavailability of Androstenedione can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Androstenedione can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Androstenedione is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Androstenedione.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Androstenedione.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Androstenedione.Approved
MefloquineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Androstenedione.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Androstenedione.Approved
MesteroloneAndrostenedione may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Androstenedione can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Androstenedione.Investigational, Withdrawn
MethallenestrilThe serum concentration of Androstenedione can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Androstenedione is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideAndrostenedione may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Androstenedione.Approved, Vet Approved
MethyltestosteroneAndrostenedione may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Androstenedione is combined with Metoclopramide.Approved, Investigational
MetolazoneAndrostenedione may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Androstenedione can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Minaprine.Approved
MitotaneThe serum concentration of Androstenedione can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Androstenedione.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Androstenedione.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Androstenedione.Experimental
MoxestrolThe serum concentration of Androstenedione can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Androstenedione.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Androstenedione.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Androstenedione.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Androstenedione.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Androstenedione.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Androstenedione is combined with Nalidixic Acid.Approved, Investigational
NandroloneAndrostenedione may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateAndrostenedione may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Androstenedione.Approved, Vet Approved
NefazodoneThe serum concentration of Androstenedione can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Androstenedione can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Androstenedione.Approved
NevirapineThe serum concentration of Androstenedione can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Androstenedione is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Androstenedione.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Androstenedione.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Androstenedione.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Androstenedione.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Androstenedione.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Androstenedione.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Androstenedione.Vet Approved
OxandroloneAndrostenedione may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Androstenedione.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Androstenedione is combined with Oxolinic acid.Experimental
OxymetholoneAndrostenedione may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Androstenedione.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Androstenedione is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Androstenedione.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Androstenedione.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Androstenedione can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Androstenedione can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Androstenedione.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Androstenedione.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Androstenedione.Approved, Investigational
PhenytoinThe serum concentration of Androstenedione can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Androstenedione.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Androstenedione is combined with Pipemidic acid.Experimental
PiretanideAndrostenedione may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Androstenedione.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Androstenedione is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Androstenedione.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Androstenedione.Experimental
Polyestradiol phosphateThe serum concentration of Androstenedione can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideAndrostenedione may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Androstenedione can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Androstenedione.Experimental, Investigational
PrimidoneThe serum concentration of Androstenedione can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Androstenedione.Experimental
PromestrieneThe serum concentration of Androstenedione can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Androstenedione.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Androstenedione.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Androstenedione.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Androstenedione.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Androstenedione can be increased when it is combined with Quinestrol.Approved
QuinethazoneAndrostenedione may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Androstenedione.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Androstenedione.Approved, Experimental, Investigational
RifabutinThe serum concentration of Androstenedione can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Androstenedione can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Androstenedione can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Androstenedione.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Androstenedione.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Androstenedione.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Androstenedione is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Androstenedione.Approved
SaquinavirThe serum concentration of Androstenedione can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Androstenedione can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Androstenedione.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Androstenedione.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Androstenedione.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Androstenedione can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Androstenedione is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Androstenedione.Investigational
St. John's WortThe serum concentration of Androstenedione can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololAndrostenedione may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Androstenedione can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Androstenedione.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Androstenedione.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Androstenedione.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Androstenedione.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Androstenedione can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Androstenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Androstenedione.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Androstenedione is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Androstenedione.Approved, Withdrawn
TelithromycinThe serum concentration of Androstenedione can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Androstenedione.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Androstenedione.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Androstenedione.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Androstenedione.Approved
TestosteroneAndrostenedione may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateAndrostenedione may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Androstenedione is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Androstenedione.Approved
TiboloneThe serum concentration of Androstenedione can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Androstenedione.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Androstenedione.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Androstenedione.Approved
TorasemideAndrostenedione may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Androstenedione.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Androstenedione.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Androstenedione is combined with Trichlorfon.Vet Approved
TrichlormethiazideAndrostenedione may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Androstenedione.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Androstenedione.Approved
TromethamineThe bioavailability of Androstenedione can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Androstenedione is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Androstenedione.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Androstenedione is combined with Zoster vaccine.Approved
VoriconazoleThe serum concentration of Androstenedione can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinAndrostenedione may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Androstenedione is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Androstenedione.Approved, Investigational
ZeranolThe serum concentration of Androstenedione can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Androstenedione.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Androstenedione.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Angela M. H. Brodie, Harry J. Brodie, David A. Marsh, "Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis." U.S. Patent US4235893, issued October, 1962.

US4235893
General References
Not Available
External Links
Human Metabolome Database
HMDB00053
KEGG Drug
D00051
KEGG Compound
C00280
PubChem Compound
6128
PubChem Substance
46508011
ChemSpider
5898
BindingDB
91713
ChEBI
16422
ChEMBL
CHEMBL274826
HET
ASD
PDB Entries
1eup / 1qyx / 1xf0 / 2vct / 2vcv / 3cas / 3eqm / 3iw1 / 3nbr / 3nhx
show 13 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)158 °CPhysProp
water solubility57.8 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.75HANSCH,C ET AL. (1995)
logS-3.69ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.027 mg/mLALOGPS
logP2.93ALOGPS
logP3.93ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)19.03ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity83.61 m3·mol-1ChemAxon
Polarizability33.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9793
Caco-2 permeable+0.8011
P-glycoprotein substrateSubstrate0.5526
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.6615
Renal organic cation transporterNon-inhibitor0.6632
CYP450 2C9 substrateNon-substrate0.8548
CYP450 2D6 substrateNon-substrate0.9131
CYP450 3A4 substrateSubstrate0.7193
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9387
CYP450 2D6 inhibitorNon-inhibitor0.9386
CYP450 2C19 inhibitorNon-inhibitor0.8138
CYP450 3A4 inhibitorNon-inhibitor0.8483
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8067
Ames testNon AMES toxic0.9508
CarcinogenicityNon-carcinogens0.9313
BiodegradationNot ready biodegradable0.9343
Rat acute toxicity1.5360 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7599
hERG inhibition (predictor II)Non-inhibitor0.7469
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11.2 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MSGC-MSsplash10-004l-5910000000-518e1ad38bcc73325b53
GC-MS Spectrum - GC-MSGC-MSsplash10-004l-5910000000-5172e05f9889ee2bfaf4
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-000f-8940000000-f2892fe3b281d44164c8
GC-MS Spectrum - EI-BGC-MSsplash10-007d-1960000000-167f1765b095da9d603b
GC-MS Spectrum - GC-MSGC-MSsplash10-004l-5910000000-518e1ad38bcc73325b53
GC-MS Spectrum - GC-MSGC-MSsplash10-004l-5910000000-5172e05f9889ee2bfaf4
Mass Spectrum (Electron Ionization)MSsplash10-059m-3940000000-9cb32ac21e46afb2829a
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-000i-0090000000-36e848ba16b141eef47b
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-052b-9600000000-712954fc35a84c8217de
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-052b-9300000000-f8e9aa16b4b208b69f7b
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-000f-8940000000-e12025ea2b7808c64b9c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052b-6910000000-b616785c86a92f46158e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052b-9800000000-73e545a1eb2232d55371
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kb-5790000000-735473bc44dd70e29259
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kb-5790000000-114675a4457063901f2b
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Androstane steroids
Direct Parent
Androgens and derivatives
Alternative Parents
3-oxo delta-4-steroids / 17-oxosteroids / Delta-4-steroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives
Substituents
Androgen-skeleton / Oxosteroid / 17-oxosteroid / 3-oxosteroid / 3-oxo-delta-4-steroid / Delta-4-steroid / Cyclohexenone / Cyclic ketone / Ketone / Organic oxygen compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-oxo Delta(4)-steroid, 17-oxo steroid, androstanoid (CHEBI:16422) / androstane, C19 steroids (androgens) and derivatives, Androstane and derivatives, Androgens (C00280) / C19 steroids (androgens) and derivatives (LMST02020007)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Testosterone dehydrogenase (nad+) activity
Specific Function
Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.
Gene Name
HSD17B1
Uniprot ID
P14061
Uniprot Name
Estradiol 17-beta-dehydrogenase 1
Molecular Weight
34949.715 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
General Function
Steroid delta-isomerase activity
Specific Function
3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system pl...
Gene Name
HSD3B1
Uniprot ID
P14060
Uniprot Name
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
Molecular Weight
42251.25 Da
References
  1. Ishii-Ohba H, Inano H, Tamaoki B: Purification and properties of testicular 3 beta-hydroxy-5-ene-steroid dehydrogenase and 5-ene-4-ene isomerase. J Steroid Biochem. 1986 Oct;25(4):555-60. [PubMed:2945972]
Kind
Protein
Organism
Saccharopolyspora erythraea (strain NRRL 23338)
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
Specific Function
Catalyzes the NADPH-dependent conversion of 6-deoxyerythronolide B (6-DEB) to erythronolide B (EB) by the insertion of an oxygen at the 6S position of 6-DEB. Requires the participation of a ferredo...
Gene Name
eryF
Uniprot ID
Q00441
Uniprot Name
6-deoxyerythronolide B hydroxylase
Molecular Weight
45098.685 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity
Specific Function
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2....
Gene Name
AKR1C3
Uniprot ID
P42330
Uniprot Name
Aldo-keto reductase family 1 member C3
Molecular Weight
36852.89 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:01